



May 28, 2026

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

Symbol: LUPIN

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

**Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

We are pleased to enclose a Press Release titled "Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026".

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)**

Encl.: a/a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

info@lupin.com | www.lupin.com

Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026

Mumbai, Naples, Chicago, May 28, 2026: Lupin Limited (Lupin) announced that results from its Phase 1a trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, which is being held from May 29-June 2, 2026, in Chicago, IL. The abstract titled "**A phase 1 study to evaluate safety, tolerability, and pharmacokinetics of LNP8701 (SOS1 inhibitor) in subjects with metastatic solid tumors**" has been published in the **Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology** track and can be viewed on the ASCO website (<https://www.asco.org/abstracts-presentations/264586>).

The abstract reports the findings from an ongoing first-in-human study of LNP8701 in patients with solid tumors. LNP8701 is an orally administered, investigational SOS1 (Son of Sevenless1) inhibitor, designed to block SOS1-mediated RAS activation, thereby limiting oncogenic signaling that promotes tumor growth. Results indicate that LNP8701 was well tolerated with desirable safety, pharmacokinetics profile and favorable anti-tumor activity. The preliminary efficacy findings demonstrate that two patients completed LNP8701 monotherapy for 12 cycles (i.e., 1 year) and one patient completed 14 cycles with stable disease.

Vinita Gupta, CEO, Lupin, said, "The findings from the ongoing Phase 1 study highlight the emerging potential of LNP8701 and signal progress in our pursuit of novel therapies for difficult-to-treat cancers. We are encouraged by this momentum and remain committed to transforming scientific discovery into meaningful patient outcomes."

Current data suggest that LNP8701 is safe and well-tolerated across all tested dosing levels. Lupin will continue to study the efficacy of LNP8701 in its phase 1b trial in India and explore its potential to treat solid tumors both as a monotherapy and as part of a combination.

Details of the Abstract:

- Abstract Number: e15162
- Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
- Citation: J Clin Oncol 44, 2026 (suppl 16; abstr e15162)
- DOI: 10.1200/JCO.2026.44.16_suppl.e15162
- Clinical Trial Registration Number: CTRI/2024/08/072373
- **Abstract link:** <https://www.asco.org/abstracts-presentations/264586>

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit www.lupin.com or follow us on LinkedIn <https://www.linkedin.com/company/lupin>

For further information or queries please contact:

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin

rajalakshmiazariah@lupin.com

Thomas F. Gillespie III
Vice President, Global Business Development

ThomasGillespie@lupin.com